Key result
Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty was associated with transient neurological deficits in 10.5% of patients and no major or minor bleeding.
Why the study?
Does abciximab as an adjunct to angioplasty improve safety and prevent ischemic events in high-risk patients undergoing carotid or vertebrobasilar interventions?
Observational (n=19)
Does abciximab as an adjunct to angioplasty improve safety and prevent ischemic events in high-risk patients undergoing carotid or vertebrobasilar interventions?
Abciximab appears to be a relatively safe adjunct for high-risk carotid or vertebrobasilar endovascular interventions, with a low frequency of neurological events and no major bleeding.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice for high-risk angioplasty; leaves open efficacy for ischemic prevention pending randomized data.
Qureshi et al. (2000) conducted an observational in High-risk carotid or vertebrobasilar artery stenosis (n=19). Abciximab was evaluated on New neurological deficits. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty was associated with transient neurological deficits in 10.5% of patients and no major or minor bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: